StockMarketWire.com - Tiziana Life Sciences has raised GBP0.709m via the issue of 472,938 unsecured convertible loan notes (CLNs) to certain existing investors.
Funds raised by the issue of the CLNs will be used to fund the development of the Company's clinical stage assets milciclib and foralumab, to meet the Company's ongoing liabilities in respect of licence agreements, and for general working capital purposes.
Funds have been raised on the same terms as the fundraise announced on 8th December 2015.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.